Medical specialties

Acute Heart Failure (AHF) Therapeutics Market to Exhibit Fastest Growth due to Rising Prevalence Of Obesity Till 2021 | Million Insights

Retrieved on: 
Tuesday, February 5, 2019
Heart diseases, Anatomy, Organ failure, Heart failure, RTT, Medical specialties, Branches of biology

Acute heart failure syndromes comprise a broad range of clinical representations to patient conditions in some aspect of cardiac function.

Key Points: 
  • Acute heart failure syndromes comprise a broad range of clinical representations to patient conditions in some aspect of cardiac function.
  • Acute heart failure (AHF) is a common heart condition resulting out of acute and chronic heart conditions leading to cardiac function.
  • Browse research report with TOC on "Global Acute Heart Failure (AHF) Therapeutics Market" at: https://www.millioninsights.com/industry-reports/acute-heart-failure-ahf...
    By disorder type, acute heart failure (AHF) therapeutics market is segmented as left-sided heart failure, right-sided heart failure, diastolic failure and systolic failure.
  • Distribution channel segment for acute heart failure (AHF) therapeutics market comprises retail pharmacies, online pharmacies and hospital pharmacies.

KICVentures Announces Three New Developments in Spine Surgery

Retrieved on: 
Tuesday, February 5, 2019
Medical specialties, Surgery, Medicine, Orthopedic surgery, Neurosurgical procedures

MALDEN, Mass., Feb. 5, 2019 /PRNewswire-PRWeb/ --KICVentures, a Boston-based private investment firm leading in healthcare technology, announced today three exciting new developments in spine surgery in the areas of Motion Preservation and Biologics.

Key Points: 
  • MALDEN, Mass., Feb. 5, 2019 /PRNewswire-PRWeb/ --KICVentures, a Boston-based private investment firm leading in healthcare technology, announced today three exciting new developments in spine surgery in the areas of Motion Preservation and Biologics.
  • Professor Dr. K. Daniel Riew, a global leader in cervical spine surgery and an investor in AxioMed, helped the company design the cervical multi-level protocol.
  • AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs.
  • NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in all orthopedic surgery.

Oral and Maxillofacial Surgery Foundation concludes successful $1 million fundraising campaign

Retrieved on: 
Tuesday, February 5, 2019
Medical specialties, Medicine, Surgery, Oral and maxillofacial surgery, American Association of Oral and Maxillofacial Surgeons, Daniel Laskin, Journal of Oral and Maxillofacial Surgery

The Foundation established the $1 million campaign goal to honor the centennial of the American Association of Oral and Maxillofacial Surgeons (AAOMS), its parent organization that was founded in 1918 and today represents more than 9,000 oral and maxillofacial surgeons across the United States.

Key Points: 
  • The Foundation established the $1 million campaign goal to honor the centennial of the American Association of Oral and Maxillofacial Surgeons (AAOMS), its parent organization that was founded in 1918 and today represents more than 9,000 oral and maxillofacial surgeons across the United States.
  • Support also arrived from the International Association of Oral and Maxillofacial Surgeons (IAOMS), the IAOMS Foundation, the American Board of Oral and Maxillofacial Surgery (ABOMS), the American College of Oral and Maxillofacial Surgeons (ACOMS), the Canadian Association of Oral and Maxillofacial Surgeons (CAOMS), 36 state and regional OMS societies and several college and university OMS training programs.
  • Research Support Grants, which bestow $75,000 grants to research projects seeking to solve issues related to oral and maxillofacial surgery.
  • The mission of the OMS Foundation is to improve the quality and safety of patient care by advancing innovation in oral and maxillofacial surgery research and education.

Cold Plasma Market Size Worth $198.50 Million by 2026 | CAGR: 15.2%: Grand View Research, Inc.

Retrieved on: 
Tuesday, February 5, 2019
Physical sciences, Medical specialties, Branches of biology, Drug resistance, Bacteria, Astrophysics, Gases, Plasma, Multiple drug resistance, Blood plasma

In healthcare industry, plasma technology has been in use for some time and it continues to help improve various treatments.

Key Points: 
  • In healthcare industry, plasma technology has been in use for some time and it continues to help improve various treatments.
  • One of the major properties of cold plasma is the ability to kill bacteria and prevent infection.
  • The bacterial cells, including Multidrug Resistant (MDR) bacteria, are instantly killed after being exposed to cold plasma.
  • Grand View Research has segmented the global cold plasma market on the basis of pressure, application, and region:
    Cold PlasmaPressure Outlook (Revenue USD Million, 2014 - 2026)
    Cold PlasmaApplication Outlook (Revenue USD Million, 2014 - 2026)

Global Cancer Therapeutics Market 2018: Emphasis on Recurrent and Metastatic Divisions - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 5, 2019
Health, Oncology, RTT, Cancer, Metástasis, Medicine, Causes of death, Medical specialties

The "Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions" report has been added to ResearchAndMarkets.com's offering.
  • Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions presents qualitative and quantitative information on the current market dynamics that are influencing the market.
  • It covers a background to cancer, types of cancer, pathogenesis of cancer, and stages of cancer development, including the mechanisms of metastasis and recurrences.
  • Strategies of global companies engaged in the cancer therapeutic space and the profiles of top companies are also covered.

MaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD

Retrieved on: 
Tuesday, February 5, 2019
Stem cells, Health, Biotechnology, Pharmaceutical, FDA, Medical specialties, Medicine, Transplantation medicine, Clinical medicine, Hematopoietic stem cell transplantation, Graft-versus-host disease, DSMB, HSCT

MaaT Pharma announced today that its independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the companys ongoing Phase II HERACLES study ( NCT03359980 ) with lead biotherapeutic MaaT013 in steroid-resistant, gastrointestinal-predominant, acute Graft-versus-Host-Disease (SR GI aGvHD) after allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT).

Key Points: 
  • MaaT Pharma announced today that its independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the companys ongoing Phase II HERACLES study ( NCT03359980 ) with lead biotherapeutic MaaT013 in steroid-resistant, gastrointestinal-predominant, acute Graft-versus-Host-Disease (SR GI aGvHD) after allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT).
  • The DSMB confirmed the absence of safety issues during the trial from initiation until the first safety evaluation milestone of five patients treated.
  • The HERACLES study is a multi-center, single-arm, open-label study, enrolling 32 patients to evaluate the safety and efficacy of MaaT Pharmas lead microbiome restoration drug candidate MaaT013 in steroid-resistant aGvHD patients.
  • MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

Therapeutics Granted Orphan Drug Designation by the FDA for Autoimmune Hepatitis

Retrieved on: 
Tuesday, February 5, 2019
Medical specialties, Medicine, RTT, Hepatitis, Autoimmune hepatitis, Healthcare-associated infections, Hepatology, Liver, Autoimmunity, AIH, Autoimmune disease, Liver disease

Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US.

Key Points: 
  • Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US.
  • Autoimmune hepatitis (AIH), formerly called lupoid hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells causing the liver to be inflamed.
  • Individuals with autoimmune hepatitis often have no initial symptoms and the disease is detected by abnormal liver function tests.
  • The FDA Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease that affect fewer than 200,000 people in the US.

Therapeutics Granted Orphan Drug Designation by the FDA for Autoimmune Hepatitis

Retrieved on: 
Tuesday, February 5, 2019
Medical specialties, Medicine, RTT, Hepatitis, Autoimmune hepatitis, Healthcare-associated infections, Hepatology, Liver, Autoimmunity, AIH, Autoimmune disease, Liver disease

Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US.

Key Points: 
  • Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US.
  • Autoimmune hepatitis (AIH), formerly called lupoid hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells causing the liver to be inflamed.
  • Individuals with autoimmune hepatitis often have no initial symptoms and the disease is detected by abnormal liver function tests.
  • The FDA Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease that affect fewer than 200,000 people in the US.

Deep Brain Stimulation Offers Fresh Hope for Parkinson's Patients

Retrieved on: 
Tuesday, February 5, 2019
Medicine, Clinical medicine, Medical specialties, Neurotechnology, Electrotherapy, Medical devices, Neurosurgical procedures, Neuroprosthetics, Deep brain stimulation, Neurostimulation, Neurosurgery, Brain stimulation

Thanks to its technology, this medical device-called neurostimulator, sparked a revolution for Parkinson's patients, helping them lead a normal life.

Key Points: 
  • Thanks to its technology, this medical device-called neurostimulator, sparked a revolution for Parkinson's patients, helping them lead a normal life.
  • Neurosurgeon Ali Zrh, M.D., explained the deep brain stimulation treatment in detail.
  • For patients who do not respond to drug treatment at the desired level, we achieve successful results with DBS.
  • Deep brain stimulation surgery involves the placement of two electrodes into specific regions of the brain while the patient is awake.

Deep Brain Stimulation Offers Fresh Hope for Parkinson's Patients

Retrieved on: 
Tuesday, February 5, 2019
Medicine, Clinical medicine, Medical specialties, Neurotechnology, Electrotherapy, Medical devices, Neurosurgical procedures, Neuroprosthetics, Deep brain stimulation, Neurostimulation, Neurosurgery, Brain stimulation

Thanks to its technology, this medical device-called neurostimulator, sparked a revolution for Parkinson's patients, helping them lead a normal life.

Key Points: 
  • Thanks to its technology, this medical device-called neurostimulator, sparked a revolution for Parkinson's patients, helping them lead a normal life.
  • Neurosurgeon Ali Zrh, M.D., explained the deep brain stimulation treatment in detail.
  • For patients who do not respond to drug treatment at the desired level, we achieve successful results with DBS.
  • Deep brain stimulation surgery involves the placement of two electrodes into specific regions of the brain while the patient is awake.